source
- FDA issues warning letters to three Chinese API makers over record refusals and quality oversight lapsesThe FDA sent warning letters to three active pharmaceutical ingredient manufacturers based in China. Two firms were cited for refusing the agency's requests for records, while the third was found…
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.